Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meplazumab for Post-COVID-19
NCT05813587Phase 3Completed
- Sponsor
- Jiangsu Pacific Meinuoke Bio Pharmaceutical Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of meplazumab in post-COVID-19 condition (PCC), sponsored by Jiangsu Pacific Meinuoke Bio Pharmaceutical Co., Ltd.. Started Mar 2023; status: completed.
02
Drugs
meplazumab
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT05813587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813587.